Related Experiment Video
Updated: Aug 30, 2025
Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
Published on: February 9, 2019
Hybrid Lipid Nanoformulations for Hepatoma Therapy: Sorafenib Loaded Nanoliposomes-A Preliminary Study
Adrian Bartos1,2, Ioana Iancu3, Lidia Ciobanu1
1Department of Surgery, Regional Institute of Gastroenterology and Hepatology, 400162 Cluj-Napoca, Romania.
Abstract:
Sorafenib is a multikinase inhibitor that has received increasing attention due to its high efficacy in hepatocellular carcinoma treatment. However, its poor pharmacokinetic properties (limited water solubility, rapid elimination, and metabolism) still represent major bottlenecks that need to be overcome in order to improve Sorafenib's clinical application. In this paper, we propose a nanotechnology-based hybrid formulation that has the potential to overcome these challenges: sorafenib-loaded nanoliposomes. Sorafenib molecules have been incorporated into the hydrophobic lipidic bilayer during the synthesis process of nanoliposomes using an original procedure developed in our laboratory and, to the best of our knowledge, this is the first paper reporting this type of analysis. The liposomal hybrid formulations have been characterized by transmission electron microscopy (TEM), dynamic light scattering (DLS), and nanoparticle tracking analysis (NTA) that provided useful information concerning their shape, size, zeta-potential, and concentration. The therapeutic efficacy of the nanohybrids has been evaluated on a normal cell line (LX2) and two hepatocarcinoma cell lines, SK-HEP-1 and HepG2, respectively.
Insights
This study introduces sorafenib-loaded nanoliposomes, a novel nanotechnology formulation designed to improve the treatment of hepatocellular carcinoma. These nanoliposomes enhance the drug
Area of Science:
- Nanomedicine
- Drug Delivery Systems
- Hepatocellular Carcinoma Research
Background:
- Sorafenib is an effective multikinase inhibitor for hepatocellular carcinoma.
- Poor pharmacokinetics (solubility, elimination, metabolism) limit Sorafenib's clinical use.
- Nanotechnology offers potential solutions to overcome these limitations.
Purpose of the Study:
- To develop and characterize sorafenib-loaded nanoliposomes.
- To evaluate the therapeutic efficacy of this novel nanohybrid formulation.
- To address the pharmacokinetic challenges of Sorafenib in cancer therapy.
Main Methods:
- Incorporation of Sorafenib into nanoliposomes via a proprietary synthesis method.
- Characterization using transmission electron microscopy (TEM), dynamic light scattering (DLS), and nanoparticle tracking analysis (NTA).
- Evaluation of therapeutic efficacy on LX2, SK-HEP-1, and HepG2 cell lines.
Main Results:
- Successful synthesis of sorafenib-loaded nanoliposomes.
- Detailed characterization of nanoliposome size, shape, zeta-potential, and concentration.
- Initial assessment of therapeutic effects on liver cell lines.
Conclusions:
- Sorafenib-loaded nanoliposomes represent a promising nanotechnology-based approach.
- This formulation has the potential to overcome Sorafenib's pharmacokinetic limitations.
- Further research is warranted to explore its clinical application in hepatocellular carcinoma.
